Literature DB >> 12511414

Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma.

Thomas F E Barth1, Josée I Martin-Subero, Stefan Joos, Christiane K Menz, Cornelia Hasel, Gunhild Mechtersheimer, Reza M Parwaresch, Peter Lichter, Reiner Siebert, Peter Möoller.   

Abstract

Structural aberrations of the short arm of chromosome 2, mostly resulting in gains of 2p13 approximately 16, have recently been described as being highly recurrent in Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin lymphoma (cHL). As these gains consistently lead to increased copy numbers of the REL oncogene locus, we investigated the expression of the c-Rel protein in a series of 30 cHL cases with known genomic REL status as determined by comparative genomic hybridization and interphase cytogenetics. Expression of the c-Rel protein was investigated in 26 biopsies by immunohistochemistry. Distinct patterns were observed in HRS cells with no staining, cytoplasmic, and/or nuclear staining for c-Rel. All 13 samples with additional copies of the REL locus displayed nuclear staining for c-Rel, while 13 cHL samples lacking chromosome 2 (2p) gains displayed a significantly lower proportion or complete absence of HRS cells with nuclear c-Rel expression. Detailed analysis using combined immunophenotyping and interphase cytogenetics of individual HRS cells demonstrated that REL gains correlated with the presence of nuclear c-Rel staining. Additionally, in 2 cHL samples with translocation breakpoints in 2p13 approximately 16, nuclear staining of c-Rel was observed; in one of them the staining pattern was indicative of a truncated c-Rel protein. The correlation between structural aberrations involving the REL locus and nuclear c-Rel accumulation in HRS cells qualifies REL as a target gene of the frequent gains in 2p in cHL. The data suggest that REL aberrations are a genetic mechanism contributing to constitutive nuclear factor (NF)-kappa B/Rel activation in cHL.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12511414     DOI: 10.1182/blood-2002-08-2577

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

Review 1.  Genomic alterations in Hodgkin's lymphoma.

Authors:  Marc A Weniger; Thomas F E Barth; Peter Möller
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

Review 2.  Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.

Authors:  Akira Satou; N Nora Bennani; Andrew L Feldman
Journal:  Expert Rev Hematol       Date:  2019-07-31       Impact factor: 2.929

3.  CAPERalpha is a novel Rel-TAD-interacting factor that inhibits lymphocyte transformation by the potent Rel/NF-kappaB oncoprotein v-Rel.

Authors:  Jui Dutta; Gaofeng Fan; Céline Gélinas
Journal:  J Virol       Date:  2008-08-27       Impact factor: 5.103

Review 4.  Unexpected functions of nuclear factor-κB during germinal center B-cell development: implications for lymphomagenesis.

Authors:  Ulf Klein; Nicole Heise
Journal:  Curr Opin Hematol       Date:  2015-07       Impact factor: 3.284

5.  Hodgkin lymphoma cell lines are characterized by a specific miRNA expression profile.

Authors:  Johan H Gibcus; Lu Ping Tan; Geert Harms; Rikst Nynke Schakel; Debora de Jong; Tjasso Blokzijl; Peter Möller; Sibrand Poppema; Bart-Jan Kroesen; Anke van den Berg
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

6.  A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models.

Authors:  Wei Wei; Yuquan Lin; Zhihui Song; Wenming Xiao; Liqi Chen; Jiejing Yin; Yan Zhou; Stefan K Barta; Michael Petrus; Thomas A Waldmann; Yibin Yang
Journal:  Clin Cancer Res       Date:  2020-04-16       Impact factor: 12.531

Review 7.  The biology of Hodgkin's lymphoma.

Authors:  Ralf Küppers
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

8.  A unique cytogenetic abnormality, t(2;7)(p13.1;p21.3), in a Philadelphia-positive chronic myeloid leukemia.

Authors:  Walid Al-Achkar; Abdulsamad Wafa; Faten Moassass; Thomas Liehr
Journal:  Oncol Lett       Date:  2012-05-17       Impact factor: 2.967

9.  Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile.

Authors:  M Chin; M Herscovitch; N Zhang; D J Waxman; T D Gilmore
Journal:  Oncogene       Date:  2009-04-20       Impact factor: 9.867

10.  Prognostic impact of C-REL expression in diffuse large B-cell lymphoma.

Authors:  Choladda V Curry; April A Ewton; Randall J Olsen; Brent R Logan; Hector A Preti; Yao-Chang Liu; Sherrie L Perkins; Chung-Che Chang
Journal:  J Hematop       Date:  2009-02-13       Impact factor: 0.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.